不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
原发性和继发性中枢神经系统结外自然杀伤/T 细胞淋巴瘤患者的临床分析
英文原题：Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
查看英文原题
Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
结外自然杀伤（NK）/T细胞淋巴瘤（NKTL）是一种罕见的非霍奇金淋巴瘤，极少单独发生于中枢神经系统（CNS）或转移至CNS。在全球范围内，NKTL累及CNS预示着严重的预后，且尚无标准治疗方案。2006年至2020年间随访的414例ENKL患者中，有19例（4.59%）被诊断为CNS受累。2例患者为原发性CNS（PCNS）NKTL，17例患者为继发性CNS（SCNS）侵犯。共有9例患者存活，10例患者死亡。中位总生存时间为55个月，CNS侵犯后的中位生存时间为17个月。5年累积生存概率为45.7%。总之，对于NK/T细胞淋巴瘤预后指数风险分组III/IV的患者，可进行CNS风险评估和预防性治疗。在治疗方面，可选择以甲氨蝶呤为基础的系统治疗联合放疗和鞘内化疗。
展开英文摘要原文
Extranodal natural killer (NK)/T-cell lymphoma (NKTL) is a rare non-Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is no standard treatment. 19 of 414 patients (4. 59%) with ENKL followed were diagnosed with CNS involvement between 2006 and 2020.
Two patients had primary CNS (PCNS) NKTL, and 17 patients had secondary CNS (SCNS) invasion. A total of 9 patients survived and 10 patients died. The median overall survival time was 55 months, and the median survival time after CNS invasion was 17 months. The 5-year cumulative survival probability was 45. 7%.
In conclusion, CNS risk evaluation and prophylaxis treatment can be carried out for patients with NK/T-cell lymphoma prognostic index risk group III/IV. In terms of treatment, systemic therapy based on methotrexate combined with radiotherapy and intrathecal chemotherapy can be selected.
论文信息
- 作者
- Li X、Yu H、Fu X、Zhang L、Li X、Li L、Wang X、Sun Z
- 单位
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.China
- 期刊
- Hematological oncology2023 Apr
- 原文标识
- PubMed 34061378 · DOI 10.1002/hon.2894